Meetings to be held on April 29 and May 1 hosted by Maxim Group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
- NeuroBo Pharmaceuticals files $150M mixed securities shelf
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
- NeuroBo Pharmaceuticals cleared to continue Phase 2a trial of DA-1241
- NeuroBo Pharmaceuticals names Marshall Woodworth as CFO